Plain-language guides on GLP-1 medications, how to get a prescription, what insurance actually covers — from a brand that's genuinely on your side.
Guides for every stage of the GLP-1 journey — written with care, not clinical distance.
We've reviewed the leading GLP-1 telehealth platforms — vetted for quality, transparency, and genuine patient support.
Affiliate disclosure: Fernwell may earn a commission if you sign up through our links — this never influences our editorial recommendations.
These are the real barriers patients face — and why Fernwell exists.
Sources: IQVIA Institute, JAMA , KFF Health Tracking Poll 2024
Curated by our team. Affiliate links keep Fernwell free — always disclosed, never compromised.
Everything you need before your first appointment — insurance questions to ask, side effects to prepare for, and how to talk to your doctor. Free, always.
Same basic mechanism, very different approvals, doses, and insurance coverage. Here's what matters when you're choosing between them.
There are currently four main GLP-1 medications you'll encounter: Ozempic and Wegovy (both semaglutide), and Mounjaro and Zepbound (both tirzepatide). The drugs within each pair are chemically identical — what differs is the approved dose and the FDA-approved indication, which has enormous consequences for insurance coverage.
The single most important thing to know: Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for weight loss. Same molecules, different labels — and insurance treats them completely differently.
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk. It mimics the GLP-1 hormone your body releases after eating, slowing digestion and reducing appetite. Both Ozempic and Wegovy contain semaglutide — the difference is the maximum approved dose and the approved use.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval | Type 2 diabetes | Chronic weight management |
| Max approved dose | 2mg/week | 2.4mg/week |
| Administration | Weekly injection | Weekly injection |
| Insurance coverage | Broad (diabetes) | Limited (weight loss) |
| List price (without insurance) | ~$900/month | ~$1,350/month |
| Average weight loss (clinical trials) | ~15% body weight | ~15% body weight |
In practice, many doctors prescribe Ozempic off-label for weight loss because insurance covers it more readily for patients with diabetes or prediabetes. This is common and legal, but worth discussing with your provider.
Tirzepatide, made by Eli Lilly, is a dual GIP and GLP-1 receptor agonist — it works on two hormone pathways instead of one. Clinical trials showed higher average weight loss than semaglutide, making it the most effective GLP-1 option currently available.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA approval | Type 2 diabetes | Chronic weight management |
| Max approved dose | 15mg/week | 15mg/week |
| Administration | Weekly injection | Weekly injection |
| Insurance coverage | Broad (diabetes) | Limited (weight loss) |
| List price (without insurance) | ~$1,000/month | ~$1,060/month |
| Average weight loss (clinical trials) | ~21% body weight | ~21% body weight |
The honest answer is: it depends on your diagnosis, your insurance, and your provider's judgment. Here's a simple framework:
Important: All GLP-1 medications require a prescription from a licensed physician who has reviewed your health history. This guide is for education only — your provider will make the final recommendation based on your individual situation.
During the semaglutide shortage, the FDA allowed compounding pharmacies to produce semaglutide. Many telehealth platforms now offer compounded semaglutide at significantly lower prices than branded versions. Compounded tirzepatide is also available through some providers.
Compounded GLP-1s are not FDA-approved as branded drugs are, but they contain the same active ingredient. The quality depends heavily on the compounding pharmacy. Fernwell's recommended telehealth partners use licensed, regulated compounding pharmacies.
The side effect profiles are similar across all four medications — nausea, vomiting, constipation, and diarrhea are the most common, especially when starting or increasing dose. Tirzepatide may have a slightly different tolerability profile for some patients. See our full side effects guide for practical management tips.
Telehealth vs. in-person, what to say to your doctor, and how to navigate a denial — the fastest paths to getting started on medication.
You have two main options for getting a GLP-1 prescription: going through a telehealth platform or working with your existing primary care doctor. Both are valid — the right choice depends on your insurance, timeline, and comfort with each approach.
Telehealth platforms like Found, Ro Body, and Hims/Hers have streamlined the GLP-1 prescription process into a fully online flow. Here's what to expect:
Timeline: Most patients receive their first shipment within 5–10 days of completing their telehealth questionnaire. Some platforms offer expedited options.
If you have an existing relationship with a doctor, starting that conversation can be the most straightforward path — especially if you have type 2 diabetes or other conditions that make you a clear candidate.
Many patients feel awkward bringing up weight loss medication. Here are some clear, factual ways to open the conversation:
Some primary care doctors are still cautious about prescribing GLP-1s for weight loss, particularly without a diabetes diagnosis. If this happens, you have options:
Eligibility requirements: Most GLP-1 prescribers require a BMI of 30+ for weight loss, or BMI 27+ with at least one weight-related condition. For diabetes management, BMI thresholds are less strict. Your provider will assess your individual situation.
| Telehealth | Primary Care Doctor | |
|---|---|---|
| Speed | 24–72 hours | Days to weeks (appointment wait) |
| Cost | $99–$349/month (includes Rx) | Co-pay + separate pharmacy cost |
| Insurance | Some platforms bill insurance | Usually billable to insurance |
| Ongoing support | Varies by platform | Depends on your doctor |
| Best for | Speed, convenience, no existing relationship | Existing conditions, prefer in-person |
Coverage has changed dramatically. Here's the current state of insurance for Ozempic, Wegovy, Mounjaro, and Zepbound — and what to do when you're denied.
GLP-1 insurance coverage is one of the most rapidly changing areas in US healthcare. The short version: coverage for diabetes indications (Ozempic, Mounjaro) is broad and well-established. Coverage for weight loss indications (Wegovy, Zepbound) is improving but still inconsistent and often requires prior authorization.
Medicare Part D now covers Wegovy for patients with established cardiovascular disease (heart attack, stroke, or cardiovascular disease history) who also have obesity. This was a landmark change following the SELECT trial results showing semaglutide's cardiovascular benefits. Medicare does not broadly cover GLP-1s for weight loss alone without the cardiovascular indication.
Medicare tip: If you have a history of cardiovascular events, ask your provider specifically about documenting your cardiovascular risk. This is the key to Medicare coverage of Wegovy.
Coverage varies enormously by employer and plan. Many large employers are now adding GLP-1 coverage for weight loss, but many still exclude it. Here's a general overview:
| Drug | Typical commercial coverage | Notes |
|---|---|---|
| Ozempic | Usually covered (diabetes) | Prior auth often required for A1C criteria |
| Mounjaro | Usually covered (diabetes) | Stronger evidence → broader approval |
| Wegovy | Increasingly covered (weight loss) | Many plans still exclude; PA often required |
| Zepbound | Growing coverage | Newer approval; coverage expanding in 2025–26 |
Prior authorization (PA) means your insurer requires your doctor to submit clinical documentation before they'll cover the medication. It's frustrating but common. Here's how to improve your chances:
Insurance denials are not the end of the road. Approximately 40–60% of GLP-1 prior authorization appeals succeed with proper documentation.
You're entitled to a written explanation of any coverage denial. This tells you exactly what to address in your appeal.
Your insurer must have an appeals process. Your doctor's office can often submit this on your behalf. Include any additional clinical documentation — peer-reviewed studies on GLP-1 efficacy, your full medical record, and a letter of medical necessity from your doctor.
Both Novo Nordisk and Eli Lilly offer savings programs. Eligible commercially-insured patients may pay as little as $25/month. These don't work with Medicare or Medicaid but are valuable for those with commercial insurance who've been denied.
If insurance appeals fail, compounded semaglutide through a telehealth platform typically costs $200–$400/month — significantly less than branded medication without insurance.
Nausea, constipation, fatigue — the most common GLP-1 side effects explained honestly, with practical tips that actually work from real patient experience.
GLP-1 medications work by slowing gastric emptying — food moves through your stomach more slowly, which reduces appetite but also causes the GI symptoms that bother some patients. These effects are dose-dependent, which is why all GLP-1s start at a low dose and increase gradually over weeks or months.
Important context: Most side effects are temporary and peak during the first 4–8 weeks or after each dose increase. The majority of patients who push through this phase find side effects significantly diminish over time.
Nausea affects roughly 20–40% of GLP-1 patients, particularly at the start and after dose increases. Here's what actually helps:
Because GLP-1s slow gut motility, constipation is common — particularly on higher doses. Don't ignore it; untreated constipation can become a reason people quit the medication.
Some patients experience fatigue, especially in the first few weeks. This is partly because you're eating significantly less — caloric restriction affects energy levels. Make sure you're:
Most GLP-1 side effects are manageable, but some warrant prompt medical attention:
Contact your provider if you experience: severe abdominal pain that radiates to your back (possible pancreatitis), significant vomiting that prevents you from keeping fluids down, symptoms of low blood sugar (if on other diabetes medications), or vision changes. These are rare but serious.
The most common reason patients stop GLP-1 medications prematurely is unmanaged nausea in the first four weeks. If you're struggling, reach out to your provider before stopping. Dose timing changes, anti-nausea medication, or temporarily slowing the dose escalation schedule can all help. Quitting because of manageable side effects means missing out on significant long-term benefits.
How to eat well when your appetite has dropped significantly — protein targets, foods to avoid, and how to make the most of reduced hunger.
The appetite suppression from GLP-1 medications is powerful. Most patients find their natural hunger dramatically reduced — which is the point. But reduced appetite also means you need to be intentional about getting enough nutrition, especially protein, when you're eating significantly less overall.
The biggest dietary risk on GLP-1: Not eating enough protein. When you're in a caloric deficit, your body can break down muscle tissue for energy. Prioritizing protein protects muscle mass and supports long-term metabolic health.
Most people on GLP-1 medications should aim for 0.7–1 gram of protein per pound of goal body weight per day. If your goal weight is 160 lbs, aim for 112–160 grams of protein daily. This sounds like a lot when you're eating less — here's how to hit it:
This is a sample high-protein, GLP-1-friendly day — adjust portions to your appetite and caloric needs:
| Meal | Example | Approx. protein |
|---|---|---|
| Breakfast | 2 scrambled eggs + Greek yogurt | ~35g |
| Lunch | Chicken breast salad with chickpeas | ~45g |
| Snack | Cottage cheese with berries | ~25g |
| Dinner | Salmon with vegetables | ~35g |
| Total | ~140g protein |
Dehydration is extremely common on GLP-1 medications. When you eat less food, you get less water from food sources. Aim for at least 8–10 glasses of water per day. Electrolytes (sodium, potassium, magnesium) can also become depleted — a low-sugar electrolyte supplement can help, especially if you're experiencing constipation or fatigue.
Most GLP-1 patients don't need to obsessively track calories — the medication does a lot of that work. However, a rough awareness of protein intake is valuable. Focus on food quality over restriction: prioritize protein and vegetables, reduce ultra-processed foods, and let the medication do its job.
What to do when weight loss stalls, how to talk to your provider about what's next, and how to think about the GLP-1 journey beyond year one.
Most patients experience a plateau — a period where weight loss slows or stalls despite continuing the medication. This is completely normal and doesn't mean the medication has stopped working. The body is complex, and weight loss is never linear.
Plateaus typically happen at one of two points: around 3–4 months in as the body adjusts to the medication, and again around 12–18 months as you approach your body's new set point. The response varies significantly between individuals.
Perspective check: Clinical trials show that maximum weight loss from GLP-1 medications typically occurs at 12–16 months, not immediately. If you're at month 3 and feel like it's not working fast enough, you may still be in the early phase.
Come to your appointment prepared with specifics. Tell your provider:
Clinical evidence is clear on one point: when patients stop GLP-1 medications, most regain significant weight within 12 months. This has led many researchers and health experts to view GLP-1s more like chronic disease medications — taken indefinitely — rather than a short-term course.
That said, this is a personal decision that depends on your health goals, insurance coverage, cost, and how your body responds. Some patients maintain results with a lower maintenance dose. Others choose to gradually discontinue with intensive lifestyle support. There's no universal right answer — this is a conversation to have with your provider.
Don't stop abruptly without a plan: If you need to stop GLP-1 medication for cost or other reasons, discuss a tapering plan and weight maintenance strategy with your provider first. Abrupt discontinuation without a support plan is associated with faster weight regain.
Average weight loss with semaglutide in trials was approximately 15% of body weight. With tirzepatide, approximately 21%. These are averages — individual results range from very modest to dramatic. Your genetics, baseline weight, lifestyle factors, and dose all play a role. Focusing on health markers (blood pressure, blood sugar, cholesterol, sleep quality, joint pain) rather than just the scale gives you a fuller picture of what the medication is doing for you.